ELAVL1 and lung carcinoma: siRNA‐based drugs targeting HuR have been proven to inhibit migration and invasion of lung cancer cells by modulating interactions between HuR and pre‐mRNA and suppressing subsequent CXCR4, MMP‐2, and MMP‐9 expression.169